Skip to main content

Table 1 Demographic data and results of cerebrospinal fluid biomarkers

From: Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease

 

Control group (n = 66)

MCI-Stable group (n = 74)

MCI-AD group (n = 70)

ADD group (n = 168)

p valuea

Age (years)

57.5 (51–68)

65 (59–73)

71 (68–76)

68.5 (62–75)

< 0.001

Female gender (%)

59

66

63

67

0.73

APOE ε4 carriers (%)

NA

28

60

46

< 0.001

MMSE

NA

28 (25–29)

25 (23–28)

18 (14–21)

0.049

Maximum follow-up (years)

NA

16.0

10.0

NA

NA

Aβ1–42 (pg/ml)

852.9 (637.7–1041.1)

780.0 (572.2–949.0)

459.6 (352.3–603.8)

388.6 (308.2–532.7)

< 0.001

Aβ1–40 (pg/ml)

8833 (6537–11,471)

10,659 (7672–13,443)

10,379 (8088–12,265)

8410 (6803–11,489)

0.53

Aβ42/40

0.100 (0.074–0.127)

0.079 (0.044–0.108)

0.046 (0.035–0.059)

0.046 (0.034–0.065)

< 0.001

Tau (pg/ml)

178.3 (141.7–221.6)

215.5 (139.6–335.5)

448.0 (302.9–638.8)

459.7 (289.3–702.8)

< 0.001

pTau181 (pg/ml)

29.6 (22.5–37.0)

33.9 (24.0–46.7)

59.0 (38.3–75.0)

55.2 (39.1–79.8)

< 0.001

  1. Continuous variables presented as median (interquartile range); proportions presented as percentage in a given group
  2. amyloid beta, AD Alzheimer’s disease, ADD Alzheimer’s disease dementia, APOE apolipoprotein E, MCI mild cognitive impairment, MMSE Mini Mental State Examination, NA not applicable
  3. aContrasting MCI-Stable and MCI-AD groups. Continuous variables tested with two-tailed t test; proportions tested with Kruskal–Wallis test